Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04234529 · ClinicalTrials.gov registry record · NA
Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study
A NA study, sponsored by University of Memphis.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT04234529 is a NA study that has completed, run by University of Memphis. The registered enrollment target is 59 participants.
The verdict
NCT04234529, a NA study, has completed, sponsored by University of Memphis.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee). In-house evaluations and anecdotal findings related to AMATEA have noted sustained energy without the typical "crash" and/or "jitters" experienced by some with caffeine ingestion alone. The aim of the present study is to compare the effects of AMATEA and caffeine alone on various measures of cognitive performance, mood, and gaming performance in men and women who regularly engage in gaming activity. The investigators hypothesize that both AMATEA and caffeine will improve outcome measures more than placebo, with greater improvement noted for the AMATEA condition due to the addition of the chlorogenic acid.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Caffeine
- DIETARY_SUPPLEMENT AMATEA™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2021-06-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04234529
The ClinicalTrials.gov registry entry for NCT04234529 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Memphis, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04234529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04234529 about?
NCT04234529 is a clinical study titled "Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study". AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee). In-house evaluations and anecdotal findings related to AMATEA have noted sustained energy without the typical ...
What is the current status of trial NCT04234529?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2020-02-01. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT04234529?
The interventions under investigation include: Placebo (OTHER), Caffeine (DIETARY_SUPPLEMENT), AMATEA™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04234529?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.